Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

JOURNAL ARTICLE published October 2020 in Investigational New Drugs

Research funded by Eisai (None)

Authors: Kenichi Inoue | Masato Takahashi | Hirofumi Mukai | Takashi Yamanaka | Chiyomi Egawa | Yukinori Sakata | Hiroki Ikezawa | Toshiyuki Matsuoka | Junji Tsurutani